Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Infertility Women ≥ 18 to ≤ 40 years of age, with one or more years infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation BMI ≥ 30 kg/m2 obtained at screening visit Normal uterine cavity and at least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography (SHG), or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the subject did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH ≤ 10 IU/L with Estradiol ≤ 70 pg/mL OR AMH ≥ 1 ng/mL within one year prior to study initiation Normal or corrected thyroid function within one year of study initiation Normal or corrected prolactin level within one year of study initiation In general good health, not taking any medications which could interfere with the study (e.g., FSH, insulin sensitizers) Ability to have inseminations following hCG administration Male partner with total motile sperm in the ejaculate of at least 5 million sperm, within one year of study initiation Able to comply with intercourse instructions and collection of semen for insemination  Currently pregnant or successful pregnancies within 12 months of initiating participation. Clinical intrauterine miscarriages prior to initiating participation, within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35 must wait 12 months. No for biochemical pregnancies Undiagnosed abnormal uterine bleeding Suspicious ovarian mass Subjects on oral contraceptives, depo-progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially when the implants are still in place. A one-month washout will be required for patients who have taken oral cyclic progestins Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal hyperplasia Type I or Type II diabetes mellitus, or if receiving antidiabetic medications Known significant anemia (Hemoglobin <10 g/dL) History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event Known heart disease (New York Heart Association Class II or higher) Known liver disease (defined as AST or ALT >2 times normal, or total bilirubin >2.5 mg/dL)